Pradnya D. Patil, MD, FACP, discusses unmet needs that remain to be addressed with the use of immunotherapy in patients with non–small cell lung cancer.
Pradnya D. Patil, MD, FACP
Advertisement
Articles by Pradnya D. Patil, MD, FACP
Pradnya D. Patil, MD, FACP, discusses the development of KRAS G12C inhibitors in lung cancer.
Pradnya D. Patil, MD, FACP, discusses data from the phase 3 ADAURA trial in patients with EGFR-mutated non–small cell lung cancer.
Pradnya D. Patil, MD, FACP, discusses recent developments with targeted therapies in lung cancer.
Advertisement
Latest Updated Articles
Dr. Patil on Key Developments With Targeted Therapy in Lung CancerPublished: August 26th 2021 | Updated:
Dr. Patil on the Development of KRAS G12C Inhibitors in Lung CancerPublished: September 13th 2021 | Updated:
Dr. Patil on ADAURA Data with Osimertinib in NSCLCPublished: September 2nd 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
NP-G1-044 Receives FDA Orphan Drug Designation for Pancreatic Cancer
3
Ixazomib-Based Regimens Expand Options in Relapsed/Refractory Multiple Myeloma
4
GLORA-4 Set to Evaluate Lisaftoclax Plus Azacitidine in Higher-Risk MDS in First-of-Its-Kind Study
5